-
-
-
-
-
-
-
Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in
-
-
-
-
-
-
-
RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018)
-
-
-
-
-
-
-
RECORDATI: PRELIMINARY 2018 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +5.0%, EBITDA +9.8%, OPERATING INCOME +8.8%, NET INCOME +8.2%
-
-
-
-
-
-
-
REC Silicon sees hope for resolving China solar dispute under Trump
-
-
-
-
-
-
-
RECORDATI : PRELIMINARY 2015 RESULTS: REVENUE GROWTH AND FURTHER MARGIN IMPROVEMENT. SALES +6.1%, OPERATING INCOME +20.6% AND NET INCOME +23.3%
-
-
-
-
-
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

